Compare CYRX & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYRX | ADCT |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | Switzerland |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.3M | 431.2M |
| IPO Year | 2008 | 2019 |
| Metric | CYRX | ADCT |
|---|---|---|
| Price | $14.77 | $1.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $13.31 | $7.75 |
| AVG Volume (30 Days) | 816.2K | ★ 3.2M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | 30.86 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $176,177,000.00 | $81,357,000.00 |
| Revenue This Year | $11.06 | N/A |
| Revenue Next Year | $8.45 | $66.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $6.69 | $0.78 |
| 52 Week High | $16.73 | $4.98 |
| Indicator | CYRX | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 19.26 |
| Support Level | $14.29 | $0.78 |
| Resistance Level | $16.73 | $4.77 |
| Average True Range (ATR) | 0.64 | 0.16 |
| MACD | -0.24 | -0.03 |
| Stochastic Oscillator | 14.52 | 11.78 |
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).